Bipolar disorder - new drugs (replaced by CG38 Bipolar disorder)
The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder
Summary
This guidance has been updated and replaced by CG38 Bipolar Disorder. The guidance that NICE has produced concerns only the use of olanzapine and valproate semisodium to treat the immediate severe (called the ‘acute’) symptoms of an episode of mania in bipolar I disorder. NICE recomme ...
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA66
Issued: September 2003
How this guidance was produced